Loss of Heterozygosity and Methylation of P16 in Renal Cell Carcinoma

Overview

Journal Urol Res

Specialty Urology

Date 2003 Jul 29

PMID 12883879

Citations 8

Authors

M T Sanz-Casla

M L Maestro

V del Barco

I Zanna

J Moreno

M Vidaurreta

I Almansa

C Fernandez

J Blanco

C Maestro

L Resel

Affiliations

Soon will be listed here.

Abstract

To investigate the possible role of genomic aberrations of chromosome 9p21 in the tumorigenesis of human renal cell carcinoma (RCC), 40 sporadic RCCs were studied using PCR analyses. The tumours were predominantly low stage and low grade. Loss of heterozygosity (LOH) was observed in nine of 39 informative cases, but no homozygous deletion was noticed. Hypermethylation of the promoter region of p16 occurred in eight of the 40 RCCs. No correlation was found between hypermethylation of the p16 gene and LOH on 9p21. A similar level of LOH and methylation was observed in the 40 RCCS regardless of histology, grade and stage. These results suggest that inactivation of p16 and the possibility of other unknown tumour suppressor genes located on other chromosomes could be involved in the pathogenesis of RCC.

Citing Articles

Clinical significance of and promoter methylation in renal cell carcinoma: a meta-analysis.

Ren Y, Xiao L, Weng G, Shi B Oncotarget. 2017; 8(38):64385-64394.

PMID: 28969078 PMC: 5610010. DOI: 10.18632/oncotarget.18826.

Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.

Liu Q, Jin J, Ying J, Sun M, Cui Y, Zhang L Int J Mol Sci. 2015; 16(5):10636-49.

PMID: 25970749 PMC: 4463666. DOI: 10.3390/ijms160510636.

Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.

El-Mokadem I, Fitzpatrick J, Bondad J, Rauchhaus P, Cunningham J, Pratt N Br J Cancer. 2014; 111(7):1381-90.

PMID: 25137021 PMC: 4183850. DOI: 10.1038/bjc.2014.420.

Alterations of the WNT7A gene in clear cell renal cell carcinomas.

Kondratov A, Kvasha S, Stoliar L, Romanenko A, Zgonnyk Y, Gordiyuk V PLoS One. 2012; 7(10):e47012.

PMID: 23056560 PMC: 3466251. DOI: 10.1371/journal.pone.0047012.

Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics.

Morris M, Maher E Genome Med. 2010; 2(9):59.

PMID: 20815920 PMC: 3092110. DOI: 10.1186/gm180.

References

Morita R, Ishikawa J, Tsutsumi M, Hikiji K, Tsukada Y, Kamidono S . Allelotype of renal cell carcinoma. Cancer Res. 1991; 51(3):820-3. View

Costello J, Berger M, Huang H, Cavenee W . Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996; 56(10):2405-10. View

Maesawa C, Tamura G, Nishizuka S, Ogasawara S, Ishida K, Terashima M . Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res. 1996; 56(17):3875-8. View

Cairns P, Tokino K, Eby Y, Sidransky D . Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res. 1995; 55(2):224-7. View

Herman J, Merlo A, Mao L, Lapidus R, Issa J, Davidson N . Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55(20):4525-30. View

Fuhrman S, Lasky L, Limas C . Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6(7):655-63. DOI: 10.1097/00000478-198210000-00007. View

Gonzalez-Zulueta M, Bender C, Yang A, Nguyen T, Beart R, Van Tornout J . Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995; 55(20):4531-5. View

Kim S, Ro J, Kemp B, Lee J, Kwon T, Fong K . Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res. 1997; 57(3):400-3. View

Cheng J, Jhanwar S, Klein W, BELL D, Lee W, Altomare D . p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994; 54(21):5547-51. View

10.

Maelandsmo G, Berner J, Florenes V, Forus A, Hovig E, Fodstad O . Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer. 1995; 72(2):393-8. PMC: 2033985. DOI: 10.1038/bjc.1995.344. View

11.

Cairns P, Polascik T, Eby Y, Tokino K, Califano J, Merlo A . Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995; 11(2):210-2. DOI: 10.1038/ng1095-210. View

12.

Gonzalgo M, Bender C, You E, Glendening J, Flores J, Walker G . Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res. 1997; 57(23):5336-47. View

13.

Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M . Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 1994; 54(20):5269-72. View

14.

Cairns P, Mao L, Merlo A, Lee D, Schwab D, Eby Y . Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 1994; 265(5170):415-7. DOI: 10.1126/science.8023167. View

15.

Foster K, Crossey P, Cairns P, Hetherington J, Richards F, Jones M . Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br J Cancer. 1994; 69(2):230-4. PMC: 1968700. DOI: 10.1038/bjc.1994.44. View

16.

Liggett Jr W, Sidransky D . Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998; 16(3):1197-206. DOI: 10.1200/JCO.1998.16.3.1197. View

17.

Greenberg R, Howard S, Bruzel A, Bremer M, Goll A, Salazar H . Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci U S A. 1995; 92(7):2854-8. PMC: 42317. DOI: 10.1073/pnas.92.7.2854. View

18.

Herman J, Latif F, Weng Y, Lerman M, Zbar B, Liu S . Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994; 91(21):9700-4. PMC: 44884. DOI: 10.1073/pnas.91.21.9700. View

19.

Shapiro G, Edwards C, Kobzik L, Godleski J, Richards W, Sugarbaker D . Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995; 55(3):505-9. View

20.

Merlo A, Herman J, Mao L, Lee D, Gabrielson E, Burger P . 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995; 1(7):686-92. DOI: 10.1038/nm0795-686. View